DOJ: "Pay-to-delay" drug agreements should be illegal

07/7/2009 | Wall Street Journal, The

Patent settlements involving "pay-to-delay" agreements between brand-name drugmakers and generics companies should be deemed unlawful, the Justice Department Antitrust Division said in a court filing. The agency's comment is in response to a lawsuit against Bayer and Barr Pharmaceuticals, which ended a patent dispute through a deal delaying the launch of a version of antibiotic Cipro.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC